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by Regulating Mitotic CENPF mRNA and Drives 
Cell-Cycle Progression Which Can Be Targeted to 
Limit Vascular Remodeling
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RATIONALE: In response to blood vessel wall injury, aberrant proliferation of vascular smooth muscle cells (SMCs) causes 
pathological remodeling. However, the controlling mechanisms are not completely understood.
OBJECTIVE: We recently showed that the human long noncoding RNA, SMILR, promotes vascular SMCs proliferation by 
a hitherto unknown mechanism. Here, we assess the therapeutic potential of SMILR inhibition and detail the molecular 
mechanism of action.
METHODS AND RESULTS: We used deep RNA-sequencing of human saphenous vein SMCs stimulated with IL (interleukin)-1α 
and PDGF (platelet-derived growth factor)-BB with SMILR knockdown (siRNA) or overexpression (lentivirus), to identify 
SMILR-regulated genes. This revealed a SMILR-dependent network essential for cell cycle progression. In particular, we 
found using the fluorescent ubiquitination-based cell cycle indicator viral system that SMILR regulates the late mitotic phase 
of the cell cycle and cytokinesis with SMILR knockdown resulting in ≈10% increase in binucleated cells. SMILR pulldowns 
further revealed its potential molecular mechanism, which involves an interaction with the mRNA of the late mitotic protein 
CENPF (centromere protein F) and the regulatory Staufen1 RNA-binding protein. SMILR and this downstream axis were 
also found to be activated in the human ex vivo vein graft pathological model and in primary human coronary artery SMCs and 
atherosclerotic plaques obtained at carotid endarterectomy. Finally, to assess the therapeutic potential of SMILR, we used a 
novel siRNA approach in the ex vivo vein graft model (within the 30 minutes clinical time frame that would occur between 
harvest and implant) to assess the reduction of proliferation by EdU incorporation. SMILR knockdown led to a marked 
decrease in proliferation from ≈29% in controls to ≈5% with SMILR depletion.
CONCLUSIONS: Collectively, we demonstrate that SMILR is a critical mediator of vascular SMC proliferation via direct regulation 
of mitotic progression. Our data further reveal a potential SMILR-targeting intervention to limit atherogenesis and adverse 
vascular remodeling.
VISUAL OVERVIEW: An online visual overview is available for this article.
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Aberrant proliferation of vascular smooth muscle cells (vSMCs) is a common and functionally important mechanism that impacts on the pathogenesis of many 
vascular diseases, including intimal thickening associated 
with remodeling of intravascular stents, coronary artery 
bypass graft failure, atherosclerosis, and aortic aneurysm 
formation. In particular, vSMC proliferation is promoted 
by the injurious microenvironment, partly through the 
increased exposure of vSMC to inflammatory cytokines 
and growth factors such as IL (interleukin)-1 and PDGF 
(platelet-derived growth factor), respectively. These often 
act in synergy to promote a proliferative phenotype with 
associated activation of critical gene networks, such as 
metalloproteinases.1–4 Clinically, targeting vSMC prolifera-
tion is exceptionally effective at reducing adverse vascular 
remodeling following balloon angioplasty and vessel stent-
ing, evidenced by extensive research and development 
of antiproliferative drug-eluting stent technologies.5,6 For 
iatrogenic vascular injury, pathogenic SMC proliferation 
causes intimal hyperplasia and luminal narrowing of blood 
vessels in the setting of vascular stenting or vein graft fail-
ure.2,7 In more complex settings, such as atherosclerosis, 
vSMC proliferation is central to the accumulation of large 
numbers of plaque-derived vSMC that not only contribute 
to the atherogenic process itself but can also confer plaque 
stabilization.8,9 Despite context-dependent heterogeneity 
in vSMC pathobiology, the underlying activation of vSMC 
proliferation is a central phenotype to the progression of 
vessel wall dysfunction. It is, therefore, imperative to further 
understand the molecular mechanisms that govern vSMC 
proliferation pathways to advance innovative therapies.
Recently, robust evidence has revealed that noncod-
ing RNAs may play a vital role in the regulation of tissue 
homeostasis, including cardiovascular homeostasis, and 
hence pathophysiological conditions.10 Mammalian genomes 
are pervasively transcribed to produce thousands of long 
Nonstandard Abbreviations and Acronyms
AurKB aurora kinase N
CENPF centromere protein F
FACS fluorescence-activated cell sorter
FUCCI  fluorescence ubiquitin cell cycle 
indicator
GFP green fluorescent protein
HCASMCs  human coronary artery smooth muscle 
cells
HSV human saphenous vein
HSVSMCs  humans saphenous vein derived smooth 
muscle cells
IL interleukin
IL1-PDGF IL-1α and PDGF-ββ–induced
lncRNA long noncoding RNA
PDGF platelet-derived growth factor
qRT-PCR  quantitative real-time polymerase chain 
reaction
RAP RNA antisense pulldown
RNA-seq RNA-sequencing
siRNA small interfering RNA
STAU1 Staufen 1
UBC ubiquitin C
vSMCs vascular smooth muscle cells
Novelty and Significance
What Is Known?
• Like other noncoding RNA, long noncoding RNA (lncRNA) 
can regulate key aspects of smooth muscle cell function.
• LncRNA SMILR regulates smooth muscle cell prolif-
eration via an unknown mechanism.
What New Information Does This Article  
Contribute?
• LncRNA SMILR regulates a network of cell cycle-
associated mRNAs in vascular smooth muscle cells.
• LncRNA SMILR binds directly to the mitotic cell regu-
lator CENPF (centromere protein F) mRNA.
• Inhibition of SMILR by RNA interference blocks vascular 
smooth muscle cell proliferation in intact saphenous vein.
Vascular smooth muscle cell proliferation has been rec-
ognized as central to the pathology of many major forms 
of vascular disease including intimal hyperplasia associ-
ated with vein graft failure. Previously, RNA-sequencing 
identified SMILR as a novel intergenic lncRNA activated 
by vascular smooth muscle cell proliferation. Under-
standing the molecular mechanisms governing the 
mode of action of SMILR is an important next step. Spe-
cific modulation of SMILR levels revealed its role in reg-
ulating a mitotic mRNA network and more specifically 
a central role for binding to the cell cycle-associated 
CENPF mRNA. Specific knockdown of SMILR resulted 
in the accumulation of binucleated cells and reduced 
proliferation and was phenotypically copied by silencing 
of CENPF. Furthermore, we show that SMILR binds the 
RNA-binding protein Stau1 (Staufen 1), which may aid 
in the regulation of cell cycle. Finally, SMILR inhibition in 
whole vein segments resulted in the reduction of smooth 
muscle cell proliferation through modulation of the key 
cell cycle network. Our findings provide compelling evi-
dence that SMILR is a novel target in the treatment of 
aberrant growth of vascular smooth muscle cells.
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noncoding RNAs (lncRNAs). LncRNAs are widely involved in 
physiological and pathological processes, such as cancer,11 
autoimmune diseases,12 and cardiac disease.13 LncRNA can 
exert their function via a broad range of activities including, 
but not limited to, chromatin remodeling, formation of nuclear 
bodies, and activities as scaffolds and guides.14 Previous find-
ings have suggested that a substantial proportion of lncRNAs 
reside within, or are dynamically shuttled to, the cytoplasm 
to regulate mRNA stability, protein translation, microRNA 
availability, and impact on protein modifications.15 Such RNA-
based regulation generally relies on lncRNA interactions with 
RNA-binding proteins.16 We previously identified the lncRNA 
SMILR by RNA-sequencing (RNA-seq) of human vSMCs 
following activation by IL-1α and PDGF-ββ signaling.17 
SMILR is an intergenic and poorly conserved lncRNA that 
consists of only a single 3-exon polyadenylated transcript 
that is vSMC-enriched, and its knockdown by RNA inter-
ference blocked IL-1α and PDGF-ββ-induced (IL1-PDGF) 
vSMC proliferation.17 Thus, we reasoned that identifying the 
downstream targets and binding partners of SMILR would 
reveal the specific mechanism by which it regulates vSMC 
proliferation and hence provide a novel therapeutic target for 
preventing adverse vascular remodeling.
METHODS
The authors declare that all supporting data and materi-
als are available within the article (and its in the Online Data 
Supplement) and available from the corresponding author 
on reasonable request. All RNA-seq data have been made 
deposited in the Gene Expression Omnibus repository, study 
number GSE120521 for the atherosclerosis RNA-seq and 
GSE117608 for SMILR RNA-seq.
Expanded information about materials and methods are 
available in the Online Data Supplement.
Declaration of Helsinki
All studies comply with the Declaration of Helsinki, that the 
locally appointed ethics committee has approved the research 
protocol and that informed consent has been obtained from 
the subjects.
Primary human saphenous vein SMCs (HSVSMCs) were 
isolated via explant technique from consented patients and cul-
tured as previously described.17 All procedures had local ethi-
cal approval (15/ES/0094). HSVSMCs from passage 3 to 5 
were used for this study, and cells were synchronized in DMEM 
containing 0.2% FBS for 48 hours before experimentation. 
Modulation of SMILR expression was performed through the 
utilization of dsiRNA or SMILR lentivirus with appropriate con-
trols and their effect on the genome was assessed via RNA-
seq and confirmed through subsequent quantitative real-time 
polymerase chain reaction (qRT-PCR) validation. All qRT-PCR 
data were analyzed via the 2-ΔΔCt method.18 This method uses 
a house keeping gene and UBC (ubiquitin C) was selected as 
a housekeeping gene due to its stability across all groups and 
conditions studied. Data are graphed as relative quantification 
normalized to the UBC housekeeping gene.18
Assessment of siRNA-SMILR on SMC cell cycle was per-
formed via fluorescence ubiquitin cell cycle indicator (FUCCI)-
fluorescence-activated cell sorter (FACS) analysis and confocal 
imaging for the percent of binucleated cells. SiRNA targeting 
AURKB was used as a positive control in these studies as previ-
ously described.19,20
To evaluate binding partners of SMILR, antisense SMILR, 
or GFP (green fluorescent protein) probes were designed. For 
each pulldown experiment, either 5 GFP or 5 SMILR probes 
were used to capture bound RNA. Before RNA extraction, RNA 
was spiked with 75 ng of total Caenorhabditis elegans RNA and 
AMA1 used as a reference gene as previously described.21 
qRT-PCR was used to assess RNA expression.
To assess if SMILR exhibited any venous/arterial differences in 
expression or function, human coronary artery SMCs (HCASMC) 
were use and cultured under the same conditions as HSVSMCs. 
Stimulation of these cells was performed under basal and IL-1/
PDGF-BB stimulated conditions as described in Ballantyne et al17 
and assessment of the effect of siRNA-SMILR on HCASMC pro-
liferation (Edu-FACS), binucleation (confocal imaging), and down-
stream target expression (qRT-PCR) was performed.
To address if SMILR exhibited any protein binding partners, 
SMILR protein pulldowns were performed using streptavidin 
magnetic beads to capture the biotinylated RNA target and 
any bound proteins from stimulated SMCs. Mass spectrometric 
analysis was used to identify proteins for subsequent down-
stream analysis and validation. Anti-Stau1 (Staufen 1) pull-
downs were used as validation with appropriate IgG control to 
confirm SMILR and other RNA target binding by qRT-PCR.
Similar to Ballantyne et al17 patients with symptomatic carotid 
artery stenosis scheduled to undergo carotid endarterectomy 
were recruited from neurovascular clinics at the Royal Infirmary 
of Edinburgh to undergo separate [18F]-fluoride and [18F]- flu-
orodeoxyglucose positron emission tomography combined with 
computed tomography scans. Regions of stable and unstable 
plaque were denoted by low and high tracer uptake respectively 
and appropriately dissected. RNA-seq was performed to assess 
transcriptomic differences between plaque sections and SMILR 
expression assessed via qRT-PCR. In situ hybridization was used 
to visualize the localization of SMILR within the plaque regions.
To assess the potential clinical utilization of siSMILR, seg-
ments of human saphenous vein obtained from consented 
patients undergoing bypass surgery were pinned down with 
minutien pins on a Sylgard coated dissection dish with the 
luminal surface facing upward for 0, 7, or 14 days with media 
refreshed every 2 days. At day 0 and after 7 and 14 days of 
culture, the vein segments were washed in PBS and snap-frozen 
for subsequent RNA extraction or fixed in 4% PFA for histology. 
Proliferation of segments was assessed through the utilization of 
Click-iT EdU Alexa Fluor 488 In Vivo Imaging Kit. Expression lev-
els of SMILR and target RNA were assessed through qRT-PCR 
analysis. For siRNA transfections, HSV segments cut in equal 
pieces of ≈1 cm2 were bathed in PBS containing 25 μmol/L 
siSMILR and scrambled siRNA control for 30 minutes in 24-well 
plate. After 30 minutes of incubation, the vein segments were 
washed with PBS and pinned down as described above. To con-
firm siRNA transfection, cy3-tagged SMILR was transfected and 
visualized along with DAPI (4′,6-diamidino-2-phenylindole) and 
α-smooth muscle actin costaining via confocal imaging.
Samples of ≥n=5 were subjected to the Shapiro-Wilk test 
to assess normal distribution followed by Student t test or 
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ANOVA. Normal distribution cannot be determined on small 
samples sizes and samples with n<5 were assumed to be 
not normally distributed and subjected to Iman and Conover 
nonparametric ranking followed by Student t test or ANOVA. 
Statistical significance P<0.05 under all conditions.
RESULTS
Manipulation of SMILR Expression Identifies a 
Target Cell Cycle Network in HSVSMCs
SMILR depletion and overexpression were previously 
shown to decrease and increase, respectively, prolifera-
tion induced by stimulation of HSVSMCs with IL1-PDGF.17 
However, no characterization of the mechanisms of regula-
tion of SMILR by IL1-PDGF was described. Accordingly, we 
sought to identify the potential transcription factor binding 
sites within the promoter region of SMILR (Online Figure 
IA). Within the 2000 bp upstream of SMILR’s transcription 
start site, we identified binding sites for transcription fac-
tors that are activated by IL-1α and PDGF-BB, including 
NF-KB (nuclear factor kappa-light-chain-enhancer of acti-
vated B cells), CEBP-β (CCAAT enhancer-binding protein 
beta), ETS1 (ETS proto-oncogene 1), AP1 (activator protein 
1), NFAT (nuclear factor of activated T cells), IRF8 (inter-
feron regulatory factor 8), MYB (MYB proto-oncogene), 
and AML (acute myeloid leukemia 1; Online Figure IB). Of 
the commercially available transcription factor inhibitors, we 
analyzed the subsequent effects on SMILR expression fol-
lowing IL1-PDGF stimulation. This identified that the upreg-
ulation of SMILR following IL1-PDGF stimulation may, in 
part, be because of activation of NF-KB (Online Figure IC 
and controls in Online Figure ID). Interestingly, SMILR over-
expression does not trigger quiesced HSVSMCs to prolifer-
ate in the absence of IL1-PDGF stimulation (Online Figure 
II). Therefore, to further determine the downstream effects 
of manipulation of SMILR levels on proliferation, RNA-seq 
was performed on stimulated HSVSMCs exposed to either 
SMILR depletion via siRNA (siSMILR) or overexpression 
via lentivirus treatment to identify a downstream SMILR-
dependent transcriptome (Figure 1A).
Quantification of miR-146a, -221 and -222 by qRT-
PCR confirmed activation of the IL-1α and PDGF-ββ 
signaling pathways, respectively (Online Figure III).22,23 
Alterations in SMILR expression levels were validated by 
qPCR (Figure 1B). Considering a fold change ≥1.5 and an 
adjusted false discovery rate P<0.05, 523 (334 downreg-
ulated and 189 upregulated) and 183 (126 upregulated 
and 57 downregulated) transcripts were significantly dif-
ferentially expressed following knockdown or overexpres-
sion, respectively (Figure 1C). As we observe opposing 
effects on proliferation with SMILR knockdown and over-
expression, we focused on the transcripts that were dys-
regulated in opposing levels. This revealed 68 transcripts 
(Figure 1C and 1D) indicating that such an approach 
might be powerful in identifying a distinct SMILR-targeted 
biological interactome. This set of SMILR-regulated genes 
was enriched for cell division-related and nucleosome 
assembly gene ontology terms (Figure 1E). Interestingly, 
analysis by STRING (Search Tool for the Retrieval of Inter-
acting Genes/Proteins)24 identified that 59% (n=40 of 
68 genes) of the overlapping genes were associated with 
a single network involved in progression through the cell 
cycle, primarily the mitotic phase (Figure 1F). The top 20 
genes identified by RNA-seq that were differentially regu-
lated genes by SMILR (Online Figure IV) were selected 
for further validation in 3 different patient saphenous vein 
derived SMCs by qRT-PCR. We observed consistent and 
robust opposing regulation of the network following SMILR 
depletion and overexpression in HSVSMCs stimulated 
with IL1-PDGF (Figure 1G and 1H). In agreement with 
the absence of proliferation phenotype after SMILR over-
expression in nonstimulated quiescent conditions, SMILR 
overexpression in nonstimulated quiescent HSVSMCs did 
not result in transcription changes of the identified net-
work (Online Figure IIB). Collectively, these data suggest 
that SMILR mechanistically targets the vSMC cell cycle in 
response to IL1-PDGF stimulation.
Manipulation of SMILR Expression Effects Cell 
Cycle Progression in vSMC
Next, we functionally assessed SMILR’s ability to directly 
target cell cycle progression in HSVSMCs. First, we 
used the FUCCI viral system as well as flow cytometric 
analysis to track the cell cycle in synchronized HSVSMCs 
stimulated with IL1-PDGF for 96 hours with and with-
out SMILR knockdown. After FUCCI viral infection, cells 
in G0/G1 and S/G2/early M cell cycle phases express 
mCherry and mAzami-Green, respectively.25 Figure 2A 
represents the color change predicted in cycling cells, 
dependent on the relative stage of cell cycle—red (G1), 
yellow/orange (G1/S), green (G2/early M), or colorless 
(late M/G0) fluorescence. AurKB (aurora kinase B), a 
well-known cell cycle and mitotic mediator, was used 
as a positive control. Notably, it is also one of SMILR’s 
downstream targets in the interactome (Figure 1F). 
Consistent with previous findings showing IL1-PDGF 
stimulation only promotes 30% of quiescent cells to pro-
liferate,17 ≈60% of the FUCCI-infected HSVSMCs stim-
ulated with IL1-PDGF were found to be colorless under 
control conditions (Figure 2B and 2C). Effective knock-
down of AurKB in the HSVSMCs (4±0.48-fold reduction 
compared to control; Online Figure V) resulted in a cell 
cycle defect with a decrease in the G1 phase (P<0.05) 
and concurrent increase in M/G0 phase (P<0.05; Fig-
ure 2B and 2C). Analysis on FUCCI-infected cells also 
revealed a clear defect in the G1 phase and increase in 
the late M/G0 phase of the cell cycle following treat-
ment with siSMILR, thereby phenocopying the effect of 
AurKB knockdown (Figure 2C). A hallmark of such a 
mitotic phase defect is the inability to correctly segregate 
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Figure 1. Transcriptomics identifies a cell cycle-associated network targeted by SMILR in proliferative vascular smooth muscle 
cells (vSMCs).  
A, Schematic of experimental design for SMILR knockdown and overexpression using dsiRNA and lentivirus (LNT), respectively. B, Validation of 
SMILR knockdown and overexpression via qRT-PCR (quantitative real-time polymerase chain reaction) of 3 technical replicates used for RNA-
sequencing (RNA-seq) from one patient sample. C, Venn diagrams illustrating the number of genes dysregulated by SMILR knockdown and 
overexpression. D, Heatmap of all overlapping 68 significant changes observed on SMILR depletion and overexpression. Fold change calculated 
compared to the average FPKM (fragments per kilobase of transcript per million mapped reads) in the control (CONT) samples. E, Gene 
Ontology (GO) terms for the SMILR-regulated gene cohort. F, Protein network of 40 proliferative and cell cycle-associated genes found to be 
dysregulated with SMILR depletion and overexpression. (Continued )
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daughter from mother cells during cytokinesis, result-
ing in cellular binucleation,26 which was evident in both 
FUCCI-infected cells treated with siAurKB and siSMILR 
(Figure 2D). Accordingly, cells treated with siSMILR 
and siAURKB were stained with DAPI and phalloidin 
and assessed for binucleation via fluorescent micros-
copy (Figure 2E and 2F). This revealed an increase in 
the percentage of binucleated cells from 7.2±0.6% and 
9.1±0.3% in nontransfected and siControls, respectively, 
to 17.1±0.4% following SMILR depletion (P<0.05), and a 
similar phenotype was observed in siAurKB-treated cells 
(20.3±1.6% binucleation; Figure 2G). Importantly, siRNA 
treatment had no significant effect on apoptosis with 
any of the siRNA-based treatments (Figure 2H). Taken 
together, these data implicate a function for SMILR in 
regulating the late mitotic phase of cell cycle in vSMCs.
SMILR Directly Targets CENPF in the Cell Cycle 
Network
With both overexpression17 and knockdown (Online Fig-
ure IV) approaches affecting SMILR expression levels 
predominantly in the cytoplasmic fraction, we, therefore, 
reasoned that SMILR could directly regulate the iden-
tified affected genes by binding to the mRNA in the 
cytoplasm. We used a database of predicted lncRNA-
RNA interactions by Terai et al27 and considered the 
top 100 genes predicted to interact with SMILR based 
on SumEnergy (Online Table I). These genes were ana-
lyzed in terms of expression level in stimulated vSMC, 
differential expression in SMILR depleted or SMILR 
overexpressed conditions, as well as differential expres-
sion on stimulation with IL1-PDGF (see filtering details 
in Online Data Supplement methods and summary in 
Online Table I). This revealed that CENPF, a mitotic 
centromere protein, was the highest-ranked mRNA 
predicted to interact with SMILR (minimum and sum 
energy of −35 and −2631 kcal/mol, respectively, Online 
Table I). The predicted interacting base pair region of 
the SMILR/CENPF mRNA interaction extends across 
51 base pairs (39–90) within the sequence of SMILR 
and 58 base pairs (3291–3349) within the coding 
sequence of CENPF transcript (Online Figure VII). We 
used RNA antisense pulldown followed by qRT-PCR 
to confirm this predicted interaction. Two sets (5 even 
and 5 odd) of 3′-biotinylated DNA capture oligonucle-
otides were designed to hybridize specifically to SMILR 
(Online Data Supplement).28,29 One set of 5 GFP-spe-
cific 3′-biotinylated DNA capture oligonucleotides were 
also used as a negative control. A schematic overview 
of the experimental design is provided in Figure 3A. The 
relative enrichment of SMILR and the CENPF mRNA 
present in both the SMILR-even and -odd pools was 
calculated with respect to the GFP pool, which was 
used as background reference. We observed a 3- and 
4-fold enrichment of SMILR with the even and odd 
probes, respectively. CENPF transcript was also coen-
riched by 13- and 7-fold in the even and odd SMILR 
pulldowns, respectively, thereby independently validating 
the predicted interaction between SMILR and CENPF 
mRNA. Importantly, MKI67 (marker of proliferation 
Ki-67) mRNA another downstream target within the 
SMILR-dependent cell cycle network was assessed in 
the even and odd SMILR pulldowns and found to not 
to be enriched—suggesting specificity for a SMILR: 
CENPF mRNA interaction within the interactome (Fig-
ure 3B). Additionally, in agreement with the RNA-seq 
data, SMILR depletion and overexpression led to a 
downregulation and upregulation of CENPF transcript 
levels, respectively (Figure 3C and 3D). While having no 
effect on apoptosis, CENPF depletion (Online Figure 
VIII) resulted in a significant decrease in EdU incorpora-
tion (Figure 3E and 3F). Additionally, similar to previous 
findings,30,31 CENPF depletion resulted in an increase 
in the percentage of binucleated cells (12.5±1.2%) 
comparable to SMILR knockdown (13.7±2.2%), which 
was significantly greater than that observed under con-
trol conditions (6.0±2.0%, P<0.05, Figure 3G and 3H). 
Importantly, knockdown of CENPF also phenotypically 
mimics the effects of SMILR knockdown on key genes 
within the cell cycle network (Figure 3I). Thus, these 
data support the concept that SMILR positively targets 
CENPF mRNA, which is critical for vSMC proliferation.
To further examine the temporal involvement of 
SMILR and CENPF transcripts in promoting IL1-PDGF 
induced proliferation, time-course experiments were 
used and show that SMILR expression is significantly 
upregulated before significant EdU+ incorporation and 
CENPF mRNA expression is detected (Online Figure 
IX). Taken together, this suggests that SMILR is required 
at the early stages of IL1-PDGF stimulation to promote 
the induction of proliferation and mitotic progression.
The SMILR:CENPF RNA Interaction Is 
Regulated by Staufen1
RNAs, including lncRNAs, have been found to occa-
sionally contain structural motifs that can interact with 
other RNAs to form functional RNA-RNA hybrids, which 
can then recruit proteins that regulate their function or 
stability.32 Accordingly, to understand whether the func-
tion of SMILR/CENPF RNA hybrid is dependent on an 
Figure 1 Continued. G and H, Further validation by qRT-PCR of the top 20 identified dysregulated proliferative and cell cycle-associated 
genes with siRNA control (siCtrl) vs siSMILR and control LNT (null LNT) vs SMILR LNT. IL indicates interleukin; MOI, multiplicity of infection; 
and PDGF, platelet-derived growth factor. *P<0.05, by Iman and Conover nonparametric ranked paired Student t test of deltaCT values 
between gene of interest and the housekeeper gene UBC (ubiquitin C), n=3 biological replicates.
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Figure 2. SMILR manipulation regulates the cell cycle of vascular smooth muscle cells (vSMC).  
A, Schematic of fluorescence ubiquitin cell cycle indicator (FUCCI) viral analysis. B, Flow cytometric analysis tracking cell cycle changes 
indicated by color changes of the FUCCI viruses. C, Bar chart representing average changes in the % of cells in each stage of the cell cycle. 
Repeated measures ANOVA for *P<0.05, Iman and Conover ranked nonparametric analysis followed by 1-way ANOVA, n=3 biological 
replicates. D, Fluorescent microscopy of humans saphenous vein derived smooth muscle cells (HSVSMCs) infected with the FUCCI 
viral system. Scale bars at 50 µm. Red arrows indicate binucleated cells. E, Schematic of characterization method of binucleated cells. F, 
Fluorescent images of HSVSMCs stained with DAPI (4′,6-diamidino-2-phenylindole) and phalloidin. Scale bars at 50 µm. Red arrows indicate 
binucleated cells. (Continued )
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RNA:protein binding interaction, we performed pulldowns 
using 3′-desthiobiotin-labeled full-length SMILR and 
protein lysates from IL1-PDGF stimulated HSVSMCs 
(Figure 4A). Mass spectrometry identified 14 potential 
SMILR-binding proteins (Figure 4B). The STAU1, known 
to be involved in mRNA decay and binds lncRNA and 
mRNA hybrids,33 was clearly enriched in SMILR pulldowns 
when compared with beads alone or control 3′-desthio-
biotin-labeled full-length GFP pulldowns (Online Fig-
ure X). Moreover, previous reports have suggested that 
STAU1 is involved in checkpoint decisions in G2 and/
or G2/M transitions, which intersects with the cell cycle 
defects observed with siSMILR.34 Hence, STAU1 seems 
to be a prime candidate partner for SMILR’s mechanism 
of action. Immunoprecipitation of STAU1 from HSVSMC 
lysates stimulated with IL-1 PDGF followed by qRT-PCR 
revealed enrichment of SMILR by 2.8±1-fold (P<0.05) 
when compared with IgG controls (Figure 4C), validat-
ing the mass spectrometry results. Additionally, we found 
that STAU1 is likely to bind to SMILR within the first half 
of its sequence, which as mentioned above, is the pre-
dicted interaction site with CENPF (Online Figures VII 
and XI). We also identified coenrichment of CENPF in the 
STAU1 pulldowns by 5.0±2.2-fold (P<0.05; Figure 4C). 
To explore the involvement of STAU1 in controlling the 
proliferative phenotype mediated by SMILR and CENPF, 
we knocked down STAU1 using dsiRNA and revealed an 
increase of SMILR and CENPF mRNA by 3.3±0.9- and 
3.0±1.1-fold, respectively (Figure 4D). We accordingly 
sought to further examine the effect of STAU1 knock-
down on the SMILR downstream targets. Analysis of the 
same 20 targets described in Figure 1, which are down-
regulated and upregulated following SMILR knockdown 
and overexpression, revealed that 7 of these genes were 
significantly upregulated with STAU1 knockdown (Fig-
ure 4E). Using RNA fluorescence in situ hybridization, we 
were also able to examine the colocalization of SMILR 
and CENPF with STAU1 knockdown (Figure 4F). This 
revealed that, when compared with control conditions, 
SMILR/CENPF transcript colocalization is not depen-
dent on STAU1 expression and that there seems to be 
increased SMILR/CENPF colocalization events with 
STAU1 KD (Figure 4F). Collectively, these data suggest 
that once SMILR expression is upregulated in IL1-PDGF 
conditions, it is able to bind to CENPF mRNA. This may 
subsequently counteract STAU1-mediated regulation, 
thereby culminating in a proliferative environment and 
cell cycle progression in vSMCs.
SMILR and the Targeted Cell Cycle Network Are 
Activated in Atherosclerosis and Ex Vivo Vein 
Model of Human Saphenous Vein
Despite context-dependent heterogeneity in vSMC 
pathobiology, defects in SMC cell cycle and hence pro-
liferation, are hallmarks of vascular pathologies including 
atherosclerosis and neointimal hyperplasia associated 
with vein graft disease.3,4,9 As SMILR is poorly conserved, 
we are limited to human disease and not animal models 
to study disease association and causality. To interrogate 
the SMILR:CENPF:STAU1 interaction in human athero-
sclerosis, we performed an RNA-seq on relatively stable 
and unstable regions dissected from fresh human carotid 
plaques obtained at carotid endarterectomy in symptom-
atic patients. Although classified as stable, these plaques 
may still contain regions of instability. This is demonstrated 
by ex vivo 18F-sodium fluoride imaging of explanted 
plaques, which was used to confirm the appropriate segre-
gation by regions of relatively more unstable versus stable 
plaque, where increased uptake of the radiotracer35 was 
more apparent in unstable dissections and less so in the 
stable regions (Figure 5A). Importantly, Principal Compo-
nent Analysis of the RNA-seq showed a clear clustering of 
the distinct regions separately and not clustering together 
within each patient sample (Figure 5B). The differential 
expression analysis confirmed the changes of protein-
coding genes linked with plaque instability, including those 
associated with inflammation, matrix remodeling, and 
calcification (Online Figure XII). SMILR expression was 
upregulated in all unstable plaque samples assessed by 
qRT-PCR (Figure 5C). Additionally, SMILR was detected 
using in situ hybridization with varying intensity across all 
carotid atherosclerotic plaques from symptomatic patients 
(Figure 5D, Online Figure XIII). STAU1 pulldowns in whole 
carotid plaques also further revealed an interaction with 
SMILR with a 2-fold enrichment compared with IgG con-
trols (P<0.01; Figure 5E). Remarkably, we also observed 
that 32 of the 40 SMILR-dependent cell cycle interactome 
were also upregulated within the unstable plaques com-
pared with stable, including CENPF (Figure 5F and 5G). 
Collectively, these data suggest that the SMILR/CENPF-
STAU1 axis is activated in unstable atherosclerosis.
With arterial and venous SMCs differing significantly, 
we sought to further investigate the role of SMILR in rela-
tion to atherosclerosis by validating its mode of action 
in HCASMCs. First, we confirmed incorporation of EdU 
in HCASMCs stimulated with IL1-PDGF. This signifi-
cantly upregulated proliferation, although as previously 
described (17, Figure 6A and 6B), the proliferative capacity 
of HCASMCs are significantly less than that observed in 
Figure 2 Continued. G, Bar chart representing the % of total cells that were binucleated. *P<0.05, Iman and Conover ranked nonparametric 
analysis followed by 1-way ANOVA vs IL (interleukin)-1α/PDGF (platelet-derived growth factor)-ββ treatment alone (I+P); + = P<0.05 vs 
siControls, n=3 biological replicates. H, Bar chart representing caspase-3 activity in HSVSMCs cultured with siRNA or hydrogen peroxide as a 
positive control. Caspase activity measured by OD405. n=3 biological replicates, vs I+P treatment. ns indicates not significant.
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Figure 3. RNA: RNA analysis reveal a SMILR: CENPF (centromere protein F) interaction.  
A, Schematic of DNA antisense biotinylated probes site for SMILR and GFP and the experimental design of RNA: RNA pulldowns. B, Bar 
charts representing relative enrichments of SMILR, CENPF, and MKI67 (marker of proliferation Ki-67) in SMILR-even and -odd pulldowns vs 
the GFP (green fluorescent protein) control pulldown. Each even and odd SMILR probe pulldown was performed once across 2 independent 
biological replicates. Effects of (C) SMILR knockdown and (D) SMILR overexpression on CENPF mRNA. **P<0.05 Iman and Conover 
nonparametric ranked analysis followed by Student t test, n=3 biological replicates. E, Representative fluorescence-activated cell sorter (FACS) 
histogram plots depicting EdU uptake in siCtrl and siCENPF treated humans saphenous vein derived smooth muscle cells (HSVSMCs). Gate 
represents EdU+ cells. F, Bar chart showing mean changes of EdU incorporation in siCtrl and siCENPF treated HSVSMCs. (Continued )
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the HSVSMCs. Nevertheless, with IL1-PDGF induced pro-
liferation in the HCASMCs, we also identified by qRT-PCR 
significant increases in SMILR, CENPF, MKI67, AURKB, 
and CDC20 transcripts (Figure 6C and 6D). Importantly 
and similar to that observed in the HSVSMCs, knockdown 
of SMILR and CENPF in HCASMCs (Online Figure XIV) 
resulted in reduction in proliferation (Figure 6E and 6F). 
Taken together, this suggests that although arterial and 
venous SMCs differ significantly, SMILR’s mechanism of 
action remains consistent.
We also assessed the SMILR: CENPF axis in the con-
text of vSMC proliferation associated with vein graft dis-
ease. Hereto, we used an ex vivo HSV model,36,37 which is 
associated with time-dependent SMC proliferation, migra-
tion, and formation of neointima over 14 days in culture 
(Figure 7A).38 We first validated this approach by moni-
toring EdU incorporation at 0, 7, and 14 days and found 
significant increases (Figure 7B and 7C). Thus, we hypoth-
esized that SMILR expression may be regulated during 
the culture period. Accordingly, saphenous veins were cul-
tured for 0, 7, or 14 days and the expression of SMILR, 
CENPF, and the downstream cell cycle-associated targets 
assessed by qRT-PCR. When compared with day 0 con-
trol, SMILR expression was increased 28±13- (P<0.05) 
and 53±19-fold (P<0.01), respectively, at day 7 and 14 
(Figure 7D). We also identified a time-dependent increase 
in CENPF expression to 8±1- (P<0.05) at day 7 and 
19±7-fold (P<0.05) at day 14 (Figure 7E). Similar to the 
qRT-PCR data obtained in Figure 6E, we are able to detect 
using immunohistochemistry increases in CENPF posi-
tive cells in the medial layer from 30% at day 0% to 51% 
at day 7 (Online Figure XV). Concordantly, expression of 
other SMILR downstream targets within the cell cycle net-
work, namely AurKB, BUB1B, MKI67, and CDC20, were 
upregulated at day 7 (22±8-, 11±3-, 22±8-, and 18±7-
fold change, respectively) and day 14 (41±14-, 34±14-, 
75±29-, and 50±31-fold change, respectively; Online Fig-
ure XVI). Overall, these data suggest that SMILR expres-
sion and its downstream network has a strong association 
with pathological remodeling in human ex vivo vein grafts.
We then sought to manipulate SMILR expression in 
the ex vivo saphenous vein graft to assess the clinical 
relevance and therapeutic potential. We, therefore, used 
a novel siRNA approach within the clinically relevant time 
window of an initial 30 minutes (clinical window from har-
vesting of the saphenous vein to grafting) before culture 
in which to attempt to knockdown SMILR. Cy3-tagged 
siSMILR was first used to visualize the successful infil-
tration of the siRNA into the vein (Figure 7F). Because 
of the limitations of the longevity of siRNA chemistry, 
by day 14 the siSMILR effects were found to be dimin-
ished (Online Figure XVII). In veins with siRNA interven-
tion leading to a significant decrease in SMILR levels 
assessed at day 7 (Figure 7G), we also observed sig-
nificant decreases in CENPF and MKI67 mRNA expres-
sion (Figure 7H and 7I). Finally, quantified proliferation by 
EdU incorporation in the cultured vein revealed a strong 
reduction from 28.7±5.3% EdU +ve/DAPI +ve nuclei in 
control conditions to 5.2±2.6% with SMILR knockdown 
(Figure 7J and 7K; P<0.01).
DISCUSSION
Aberrant growth of vSMCs is a common and function-
ally important mechanism, which may ultimately contrib-
ute to the cause of numerous cardiovascular diseases.4 
Although the general mechanism of cell cycle regulation 
is well established,39 cell-enriched regulators such as 
lncRNA are not at all well defined in terms of expres-
sion, association, and mechanism, which is crucial for 
the successful development of targeted therapeutics 
and improved knowledge of how the human transcrip-
tome can impact physiological and pathological path-
ways. Here, we identify the mechanism and downstream 
network of the vSMC-enriched human lncRNA, SMILR, 
and demonstrate its therapeutic potential in the ex vivo 
HSV model (Figure 7). This has the potential to not only 
enhance our understanding of atherogenesis, neointimal 
hyperplasia, and plaque formation but also provides a 
clear therapeutic target for future investigation in a broad 
range of cardiovascular diseases.
The human genome contains a wide range of 
lncRNAs that are dynamically expressed in a tempo-
ral and cell-specific manner. These lncRNAs can influ-
ence the level and spatial distribution of many proteins 
and mRNAs to control key aspects of cellular function. 
LncRNAs have previously been shown to modulate 
cell cycle, primarily in cancer cell lines.40,41 Additionally, 
lncRNAs, such as smooth muscle and endothelial cell-
enriched migration/differentiation-associated lncRNA 
and myocardin-induced smooth muscle lncRNA, inducer 
of differentiation, have also been previously shown to 
be influential in cardiovascular diseases and essential in 
controlling the phenotypic switching of VSMCs to main-
tain their contractile phenotype (42, 43). More recently, the 
role of MEG3 (maternally expressed 3) in patients with 
pulmonary arterial hypertension was examined which 
revealed significantly reduced MEG3 expression lev-
els in patients compared with healthy controls.44 In vitro 
siRNA silencing of MEG3 resulted in increased SMC 
Figure 3 Continued. Iman and Conover ranked nonparametric analysis followed by t test, n=3 biological replicates. *P<0.05. G, Fluorescent images 
of HSVSMCs stained with DAPI (4′,6-diamidino-2-phenylindole) and phalloidin. Scale bar represents 50 µm. Red arrows indicate binucleated cells. H, 
Bar chart representing the % of total cells that were binucleated. Iman and Conover ranked nonparametric analysis followed by Student t test *P<0.05 
vs siCtrl, n=3 biological replicates. I, The effects of CENPF knockdown on mitotic associated genes compared to effects observed with knockdown 
of SMILR, *P<0.05, by Iman and Conover ranked nonparametric analysis followed by paired t test, n=4 biological replicates.
D
ow
nloaded from
 http://ahajournals.org by on October 15, 2019
ORIGINAL RESEARCH
Mahmoud et al LncRNA SMILR’s Mechanism and Therapeutic Potential
Circulation Research. 2019;125:535–551. DOI: 10.1161/CIRCRESAHA.119.314876 August 16, 2019  545
Figure 4. STAU1 (Staufen 1) degrades the SMILR: CENPF (centromere protein F) interaction to mediate vascular smooth 
muscle cell (vSMC) proliferation.  
A, Schematic showing methodology of biotinylated SMILR pulldowns. B, Mass spectrometry identified 14-enriched SMILR-binding proteins. 
STAU1 was specifically enriched in the SMILR pulldown with 11-unique peptides detected. C, Anti-STAU1 pulldowns confirming interaction 
with SMILR and CENPF; *P<0.05, by Iman and Conover ranked nonparametric analysis followed by t test, n=3 pulldowns from 3 independent 
patient samples. D, Relative quantification of STAU1, SMILR, and CENPF expression with SiSTAU1 at 10 nmol/L. *P<0.05, by Iman and 
Conover ranked nonparametric analysis followed by t test, n=3 biological replicates. E, The effects of STAU1 knockdown on the top 20 
downregulated cell cycle-associated genes regulated by SMILR, *P<0.05, by Iman and Conover ranked nonparametric analysis followed by 
t test, n=3 biological replicates. F, RNA fluorescence in situ hybridization (FISH) for SMILR (red) and CENPF (green) in stimulated vSMCs 
under control, siSMILR, siCENPF, and siSTAU1 conditions. Scale bar represents 20 µm. Yellow arrows show some colocalization events.
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Figure 5. SMILR and the targeted cell cycle network are activated in atherosclerosis.  
A, Ex vivo 18F imaging of unstable vs stable plaques. B, Principal component analysis (PCA) of the RNA-sequencing (RNA-seq) of the stable 
and unstable samples. C, Relative FPKMs (fragments per kilobase of transcript per million mapped reads) of protein-coding genes linked with 
plaque instability, including those associated with inflammation and calcification. D, Representative images of in situ detection of SMILR in 
plaques obtained from the carotid artery derived from symptomatic patients at carotid endarterectomy (n=5 biological replicates per plaque 
type, replicates in Online Figure XII). SMILR is visualized using NBT/BCIP (nitro-blue tetrazolium and 5-bromo-4-chloro-3'-indolyphosphate; 
purple) at varying intensities across plaques exhibiting either intraplaque hemorrhage or thick fibrous cap. Nuclei are stained with fast red. 
Scale bar represents 200 µm. E, SMILR enrichment in STAU1 (Staufen 1) pulldowns in whole carotid plaques, n=6, **P<0.01, by paired 
Student t test with paired experiments matched by color. Protein network (F) and heatmap (G) of the 34 proliferative and cell cycle-associated 
genes found to be dysregulated with SMILR manipulation and unregulated in unstable plaques. L indicates arterial lumen; and NC, lipid core.
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Figure 6. Role of SMILR in human coronary artery smooth muscle cells (HCASMCs).  
A, Representative fluorescence-activated cell sorter (FACS) histogram plots depicting EdU uptake in 0.2% and I+P treated HCASMCs. 
Gate represents EdU+ cells. B, Bar chart showing mean changes of EdU incorporation in 0.2% and I+P conditions. Iman and Conover 
ranked nonparametric analysis followed by t test, n=3 biological replicates. *P<0.05. Bar charts showing relative expression of (C) SMILR 
and (D) CENPF (centromere protein F), MKI67 (marker of proliferation Ki-67), AURKB, and CDC20 by quantitative real-time polymerase 
chain reaction (qRT-PCR) in 0.2% and I+P stimulated HCASMCs. Iman and Conover ranked nonparametric analysis followed by t test, n=3 
biological replicates. **P<0.05. E, Representative FACS histogram plots depicting EdU uptake in siCtrl, siSMILR, and siCENPF treated 
HCASMCs. Gate represents EdU+ cells. F, Bar chart showing mean changes of EdU incorporation in siCtrl, siSMILR, and siCENPF 
treated cells. Iman and Conover ranked nonparametric analysis followed by t test, n=3 biological replicates, *P<0.05.
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Figure 7. SMILR modulates the proliferation of the ex vivo human saphenous vein (HSV) organ culture.  
A, Graphical representation of ex vivo HSV proliferation model. B, Quantification of EdU +ve nuclei in the media of HSV in culture expressed 
as % of EdU +ve/DAPI (4′,6-diamidino-2-phenylindole) +ve nuclei. #P<0.05, *P<0.0, * vs day 0, # vs day 7 using Iman and Conover 
ranked nonparametric analysis followed by 1-way ANOVA (n=3 biological replicates per time point). C, Representative images of HSV in 
culture stained for EdU (green) and with DAPI (blue) at day 0, 7, and 14 (n=3 biological replicates per time point). SMILR (D) and CENPF 
(centromere protein F; E) expression determined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis at day 0, 7, and 
14. *P<0.05 and ***P<0.001 vs day 0 analyzed by 1-way ANOVA (n=7). F, Left: Graphical representation of the model of HSV siSMILR 
intervention; Right: Representative image of Cy3-labeled SMILR siRNA localization in HSV at 3 d post-siSMILR intervention; (Continued )
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proliferation and migration while mechanistic investiga-
tion revealed that MEG3 regulates the p53 pathway in 
PASMCs.45 Although several lncRNAs have been identi-
fied that control key aspects of SMC and EC function, 
very little is known about their role in atherosclerosis. A 
key atherosclerotic lncRNA is ANRIL (antisense non-
coding RNA in the INK4 locus), which was identified 
via genome-wide association studies, in which several 
SNPs (single nucleotide polymorphisms) located within 
this lncRNA were associated with atherosclerosis. It was 
later identified that ANRIL regulates gene expression 
epigenetically through recruiting repressive components 
of the polycomb complexes 1 and 2 to ANRIL-target 
gene promoters via Alu-repeats.46
Here, we showed that SMILR specifically targets 
the late mitotic pathway in proliferating HSVSMCs and 
interacts with CENPF mRNA and STAU1. Two recent 
studies have demonstrated that the lncRNAs, SNHG5 
(small nucleolar RNA host gene 5), and TINCR (termi-
nal differentiation-induced ncRNA), counteract STAU1-
mediated decay to promote the stabilization of specific 
mRNAs to control tumor cell survival in colorectal cancer 
and somatic tissue differentiation, respectively.29,47 Simi-
lar to TINCR and its target mRNA PGLYRP3 (peptido-
glycan recognition protein 3), SMILR’s interaction with 
CENPF mRNA appears to occur independent of STAU1 
protein interaction as revealed by RNA fluorescence in 
situ hybridization. Although we see upregulation of both 
CENPF mRNA and SMILR with STAU1 knockdown, we 
cannot exclusively conclude whether STAU1’s interac-
tion with SMILR:CENPF mRNA is regulating CENPF at 
a post-transcriptional and post-translational stage. Addi-
tionally, STAU1 may not only affect the levels of CENPF 
at an RNA and protein levels but also regulate its sub-
cellular localization since STAU1 has been found to be 
involved in mRNA transport and localization to mediate 
further translation.48
Whether the SMILR/CENPF interaction is depen-
dent on base complementarity and/or secondary struc-
ture is a key future scientific question as the secondary 
structure of SMILR may be crucial for its localization, 
downstream interactions, and hence function.49–51 Also, 
other mRNAs might be regulated by SMILR and STAU1 
and sequencing of associated mRNAs may further pro-
vide a comprehensive network of interactions in prolif-
erating vSMCs.
Consistent with our findings, previous studies have 
indicated that STAU1 primarily binds to protein-coding 
mRNAs of key mediators of cell cycle and that STAU1 
expression and function necessarily fluctuates throughout 
the cell cycle, being highest during the S-phase and rap-
idly decreasing during mitotic progression.34 Additionally, 
STAU1 overexpression affects mitotic entry and impairs 
proliferation of transformed cells, therefore, highlighting 
STAU1-function must be inhibited in a temporally depen-
dent manner during the cell cycle for proper mitotic pro-
gression.34 With STAU1 being a ubiquitously expressed 
and a multifunctional protein, lncRNAs may be crucial 
for providing its cell-specific function and accordingly 
mediate cell-specific phenotypes. This may also be the 
case for CENPF, which is also ubiquitously expressed 
and shown to be multifunctional to control mitotic control, 
transcriptional regulation, and muscle cell differentia-
tion.52 Intriguingly, increased levels of CENPF have also 
been previously associated with increased proliferation in 
malignant conditions31 and associated with a poor prog-
nosis in human cancers.53,54 However, the mechanism 
by which increased CENPF results in increased prolif-
eration is not entirely understood. One possibility is that 
the role of CENPF in assembling kinetochore structures 
required for correct chromosome alignment and sepa-
ration during mitosis is a rate-limiting step for mitotic 
progression. Taken together, our study, therefore, sug-
gests that SMILR may provide such a critical cell-spe-
cific regulation of STAU1 and CENPF function in human 
vSMCS to trigger cell cycle progression and prolifera-
tion. Further studies are required to dissect mechanisti-
cally the consequence of CENPF mRNA regulation by 
SMILR. Particularly CENPF’s mRNA stability, transport, 
and translation as well as the intersection of this with the 
mitotic phenotype that we observe when SMILR levels 
are reduced.
SMILR was previously suggested to function, at least 
in part, by regulating its neighboring gene, HAS2 (hyal-
uronan synthase 2),17 although HAS2 is located ≈750 
kb from SMILR. However, we showed using RNA-seq 
that HAS2 is downregulated with SMILR knockdown but 
was not affected by SMILR overexpression, confirming 
previous findings.17 We also demonstrated the prolifera-
tive effects of SMILR occur in the cytoplasmic fraction 
since the siRNA approach used selectively blocked 
cytoplasmic SMILR expression and would, therefore, 
unlikely involve a direct targeting of the HAS2 gene in 
the nucleus. Here, we focused on the direct regulation 
by SMILR in the cytoplasm and find effects mediated by 
a distinct proliferative network, but we cannot rule out a 
downstream effect in the nucleus due to SMILR manip-
ulation, or indeed a further proliferative effect mediated 
selectively in the nucleus by SMILR by an independent 
mechanism. In particular, we noticed the presence of 
Figure 7 Continued. the section is costained with DAPI (blue) and for α-smooth muscle actin (α-SMA, green) at ×60 magnification. Relative 
quantification of (G) SMILR, (H) CENPF, and (I) MKI67 (marker of proliferation Ki-67) expression in HSV after siSMILR intervention at day 
7 normalized to UBC (ubiquitin C). *P<0.05, **P<0.01 by paired 2-tailed Student t test, n=5 biological replicates. J, Representative images 
of HSV post-siSMILR intervention stained for EdU (green) and with DAPI (blue). K, Mean±SEM of EdU +ve nuclei in the media of HSV after 
siSMILR intervention expressed as % of EdU +ve/DAPI +ve nuclei (n=3 biological replicates). Values are *P<0.05; vs siCtrl using Iman and 
Conover ranked nonparametric analysis followed by Student t test.
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histone mRNAs among the dysregulated genes from 
the RNA-seq data. Although histone mRNAs are not 
within the list of SMILR predicted targets, the observed 
level change at the RNA level could lead to protein level 
changes and subsequent transcriptional changes.
The upregulation or downregulation of the SMILR-
axis and its consequential effects on vSMC proliferation 
could influence numerous cardiovascular diseases. This 
was apparent in the ex vivo vein graft model in this study 
and suggests that this can influence neointimal hyperpla-
sia and hence the long-term success of revascularisation 
of vein graft after coronary artery bypass surgery. Inter-
estingly, we found a similar role for SMILR in HCASMCs 
and may, therefore, also be involved in atherosclerosis. 
However, targeting of SMILR may not be beneficial due 
to the potential reduction in stability and formation of a 
fibrous cap. Further studies are, however, required to fully 
understand the influence of the SMILR-axis with respect 
to SMC proliferation in the atherosclerotic environment 
and hence the susceptibility to plaque rupture and ulti-
mately myocardial infarction and stroke.
Significantly, within a clinically amenable timeframe, 
siRNA-based gene therapy targeting SMILR is suffi-
cient to markedly reduce proliferation in the ex vivo vein 
model. This excitingly provides a vSMC-specific target, 
which reduces the possibility of off-target effects in the 
remainder of the vessel wall, that is, inhibited re-endo-
thelialization. This strongly suggests that such an inter-
vention may reduce vein graft failure rates. Although our 
studies only show successful knockdown with siRNA for 
a limited time frame, whether this is sufficient to main-
tain a long-term antiproliferative effect is something that 
requires further studies. Nonetheless, other routes of 
SMILR-targeting gene therapy may be required for maxi-
mum longevity such as LNA-GapmeR antisense oligonu-
cleotides.13 However, antisense oligonucleotides target 
both nuclear and cytoplasmic fractions of a cell whereas 
siSMILR only has a cytoplasmic effect (Online Figure VI). 
Accordingly, the subsequent effects of antisense oligo-
nucleotides knockdown of SMILR in the nuclear fraction 
must be studied to ensure no detrimental effects.
We demonstrate that SMILR is a vSMC-enriched 
lncRNA, essential in the control of cell cycle through 
binding of CENPF mRNA and STAU1. Our studies pro-
vide early but compelling evidence that SMILR is an 
exciting and novel target in the treatment of aberrant 
growth of vascular SMCs, with the potential to signifi-
cantly reduce the rate of vein graft failure.
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